Oakworth Capital Inc. Decreases Position in Johnson & Johnson (NYSE:JNJ)

Oakworth Capital Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,650 shares of the company’s stock after selling 473 shares during the period. Oakworth Capital Inc.’s holdings in Johnson & Johnson were worth $3,080,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bond & Devick Financial Network Inc. increased its position in shares of Johnson & Johnson by 6.4% in the 3rd quarter. Bond & Devick Financial Network Inc. now owns 6,531 shares of the company’s stock valued at $1,017,000 after acquiring an additional 393 shares during the period. Worth Financial Advisory Group LLC increased its position in shares of Johnson & Johnson by 4.9% in the 3rd quarter. Worth Financial Advisory Group LLC now owns 11,537 shares of the company’s stock valued at $1,797,000 after acquiring an additional 542 shares during the period. Ritholtz Wealth Management increased its position in shares of Johnson & Johnson by 90.9% in the 3rd quarter. Ritholtz Wealth Management now owns 41,394 shares of the company’s stock valued at $6,447,000 after acquiring an additional 19,714 shares during the period. Arkadios Wealth Advisors increased its position in shares of Johnson & Johnson by 54.3% in the 3rd quarter. Arkadios Wealth Advisors now owns 71,925 shares of the company’s stock valued at $11,202,000 after acquiring an additional 25,298 shares during the period. Finally, Venture Visionary Partners LLC increased its position in shares of Johnson & Johnson by 0.4% in the 3rd quarter. Venture Visionary Partners LLC now owns 99,877 shares of the company’s stock valued at $15,558,000 after acquiring an additional 373 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.3 %

JNJ opened at $149.56 on Wednesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The company’s 50 day simple moving average is $155.83 and its two-hundred day simple moving average is $155.51. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The firm has a market capitalization of $360.41 billion, a price-to-earnings ratio of 9.32, a price-to-earnings-growth ratio of 2.44 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The business had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same period last year, the company posted $2.68 EPS. The business’s revenue was up 2.3% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.32%. The ex-dividend date is Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is presently 30.92%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Bank of America cut their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Morgan Stanley dropped their target price on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Finally, Royal Bank of Canada decreased their price target on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 17th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.86.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.